Trial reportJournal of clinical immunology2012
Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein.
Trial report in Journal of clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers.BMC cancer · 2026Article
- Total plasma immunoglobulin E level before and after canine hepatocellular carcinoma surgery.The Journal of veterinary medical science · 2026Article
- The role of immunoglobulin E in non-atopic disorders.Frontiers in immunology · 2025Review
- Article
- Radiation-based immunogenic vaccine combined with a macrophage "checkpoint inhibitor" for boosting innate and adaptive immunity against metastatic colon cancers.Acta pharmaceutica Sinica. B · 2024Article
- CEA vaccines.Human vaccines & immunotherapeutics · 2023Review
- Immunomodulation of B Lymphocytes by Prebiotics, Probiotics and Synbiotics: Application in Pathologies.Nutrients · 2023Review
- Transmissible cancer influences immune gene expression in an endangered marsupial, the Tasmanian devil (Sarcophilus harrisii).Molecular ecology · 2022Article
- Immunoglobulin A, an Active Liaison for Host-Microbiota Homeostasis.Microorganisms · 2021Review
- Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments.Cancers · 2021Review
- IgM and IgA augmented autoantibody signatures improve early-stage detection of colorectal cancer prior to nodal and distant spread.Clinical & translational immunology · 2021Article
- Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.BMC immunology · 2020Article
- Function and dysfunction of plasma cells in intestine.Cell & bioscience · 2019Review
- Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination.Oncology letters · 2018Article
- History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.Surgery today · 2017Review
- Article
- Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.Bioengineering (Basel, Switzerland) · 2017Article
- IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses.Cell reports · 2015Article
- Novel and emerging targeted-based cancer therapy agents and methods.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood.Cancer immunology, immunotherapy : CII · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrevious clinical studies have indicated that natural IgM antibodies have the ability to induce apoptosis of tumor cells but IgE and IgA may also mediate tumor cell killing (in addition to IgG). The aim of the study was to analyse induction of IgM, IgA and IgE antibodies in patients vaccinated with the tumor associated antigen CEA.
methodsTwenty-four resected CRC patients without macroscopic disease were immunized seven times with CEA ± GM-CSF. Four different dose schedules were used over a 12-month period. IgM, IgA and IgE antibody responses against recombinant CEA were determined by ELISA. Patients were monitored immunologically for 36 months and clinically for 147 months.
resultsGM-CSF significantly augmented the anti-CEA response for all three antibody classes. Low dose of CEA tended to induce a higher IgM, IgA or IgE anti-CEA antibody response than higher. Anti-CEA IgA antibodies could lyse CEA positive tumor cells in antibody dependent cellular cytotoxicity (ADCC) as well as in complement dependent cytotoxicity (CDC). A significant correlation between survival and high IgA anti-CEA titers was noted (p = 0.02) irrespective of GM-CSF treatment.
conclusionsThe observation that IgA anti-CEA antibodies were cytotoxic and associated with improved survival might indicate that also these antibodies may exert a clinical anti-tumor effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.